^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    UCHL1 inhibitor

    Related drugs:
    9d
    Potential Anti-Cancer Drug 6RK73 Suppresses Ovarian Cancer Growth by Inactivating the AKT1/Sp1 Induced c-Myc Signaling Pathway. (PubMed, J Cancer)
    Finally, AKT1 overexpression reversed the 6RK73-mediated suppression of cell proliferation by reactivating the AKT1/Sp1/c-Myc signaling pathway. These findings suggest that 6RK73 is a promising anti-cancer agent that exerts its effects by inactivating AKT1/Sp1/c-Myc signaling in ovarian cancer.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    6RK73
    almost3years
    Pivotal Role of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) in Uterine Leiomyoma. (PubMed, Biomolecules)
    In conclusion, these results indicate that UCHL1 is involved in the growth of leiomyoma in humans. For the treatment of uterine leiomyoma, targeting UCHL1 activity may be a unique and possible therapeutic strategy.
    Journal
    |
    COL1A1 (Collagen Type I Alpha 1 Chain) • COL3A1 (Collagen Type III Alpha 1 Chain)
    almost4years
    Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma. (PubMed, Clin Transl Med)
    Androgen and AR function as facilitators in Xp11.2 tRCC progression and may be a novel therapeutic target for Xp11.2 tRCC. The combined use of AR antagonist MDV3100 and UCHL1 inhibitor 6RK73 increased both the SUMOylation and ubiquitination of the PRCC-TFE3 fusion protein.
    Journal
    |
    AR (Androgen receptor) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • PRCC (Proline Rich Mitotic Checkpoint Control Factor)
    |
    PRCC-TFE3 fusion • TFE3 translocation • TFE3 fusion
    |
    Xtandi (enzalutamide) • 6RK73